&lt;p&gt;Successful Deferasirox Rechallenge and Treating Through Reaction in a Patient with Challenge-Proven Mild Immediate Reaction: A Case Report&lt;/p&gt;

Sompornrattanaphan, Mongkhon; Krikeerati, Thanachit; Wongsa, Chamard; Thongngarm, Torpong; Yampayon, Kittika

doi:10.2147/jaa.s271742

Cited by 6 publications

(6 citation statements)

References 11 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the top positions in the ranking reported in Supplementary File S7, we find drugs with known effects in asthma patients or animal models of asthma, and one of these went into clinical trial stage: deferasirox [Sompornrattanaphan et al, 2020], rosiglitazone [Lee et al, 2016], valproic acid 2 , dexamethasone [Sarkari, 2007], celecoxib [Martin-Garcia et al, 2003], and tamoxifen [Mansilla et al, 2020]. Rosiglitazone has been tested on a murine model of chronic asthma [Lee et al, 2016], suggesting that its intranasal administration can prevent air way inflammation.…”

Section: Drugmerge Results On Asthmamentioning

confidence: 99%

Drug Repositioning by Merging Active Subnetworks Validated in Cancer and COVID-19

Lucchetta

Pellegrini

2021

Preprint

View full text Add to dashboard Cite

Computational Drug Repositioning aims at ranking and selecting existing drugs for use in novel diseases or existing diseases for which these drugs were not originally designed. Using vast amounts of available omic data in digital form within an in silico screening has the potential for speeding up considerably the shortlisting of promising candidates in response to outbreaks of diseases such as COVID-19 for which no satisfactory cure has yet been found. We describe DrugMerge as a methodology for preclinical computational drug repositioning based on merging multiple drug rankings obtained with an ensemble of Disease Active Subnetwork construction algorithms. DrugMerge uses differential transcriptomic data from cell lines/tissues of patients affected by the disease and differential transcriptomic data from drug perturbation assays, in the context of a large gene co-expression network. Experiments with four benchmark diseases (Asthma, Rheumatoid Arthritis, Prostate Cancer, and Colorectal Cancer) demonstrate that our method detects in first position drugs in clinical use for the specified disease, in all four cases. Our method is competitive with the state-of-the-art tools such as CMAP (Connectivity Map). Application of DrugMerge to COVID-19 data found rankings with many drugs currently in clinical trials for COVID-19 in top positions, thus showing that DrugMerge is able to mimic human expert judgment

show abstract

Section: Drugmerge Results On Asthmamentioning

confidence: 99%

Drug Repositioning by Merging Active Subnetworks Validated in Cancer and COVID-19

Lucchetta

Pellegrini

2021

Preprint

View full text Add to dashboard Cite

show abstract

“…On extensive literature search, we came across few similar case report in a thalassemia patient. A report of challenge-proven DFX-induced immediate hypersensitivity reaction was published in 2020 (10). They performed a graded challenge with treating through the reactions, ill-de ned erythematous macules and lip angioedema, using H1-antihistamine.…”

Section: Discussionmentioning

confidence: 99%

“…They performed a graded challenge with treating through the reactions, ill-de ned erythematous macules and lip angioedema, using H1-antihistamine. The patient nally developed tolerance to the drug as the patient could discontinue H1-antihistamine (10).…”

Section: Discussionmentioning

confidence: 99%

“…Those protocols took several days to achieve the target dose. There have been few reports on a n immediate hypersensitivity reaction (10)(11)(12)(13)(14). Therefore, we report a case of challengeproven immediate skin drug reaction in a TM patient with a long history of receiving deferoxamine (DFO) with no complications.…”

Section: Introductionmentioning

confidence: 96%

“…The common adverse effects of deferasirox are gastrointestinal events (15.2%), skin rash (10. 8%), and a transient increase in serum creatinine and elevations in liver enzyme levels (38%) (10)(11)(12)(13).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Dermatopathological Drug Reaction in Thalassemia Major: A Case Report and a Brief Review

Shirkavand

Ataie‐Fashtami

Azarkeivan³

et al. 2022

Preprint

View full text Add to dashboard Cite

Background: Thalassemia comprises a group of hereditary hemoglobinopathies. Thalassemia major presents with anemia within the first two years of life. These patients require frequent long-life blood transfusions for survival, leading to iron deposition in vital organs as related complications. The prognosis of Thalassemia major has improved because of the availability of iron‑chelating agents. Oral iron chelators are the mainstay of the chelation regimen. Deferasirox is a new‑generation oral iron chelator for daily usage. This case was novel for the severe, generalized dermatopathological drug reaction due to the generic form of deferasirox.Case presentation: This is a case presentation of adverse reaction in a TM patient who received oral deferasirox for the first time after years of Deferoxamine injection without any adverse reaction. There were generalized maculopapular, deep red- blue partly purpuric itchy skin rashes all over the body. The histopathological biopsy showed superficial perivascular or dermatitis with low-grade vasculopathy feature, few eosinophils, and mild psoriasiform-spoaglotic-lichenoid epidermal reaction more compatible with a clinical diagnosis of Drug ReactionConclusions: In the case of intrinsic characteristics, it is wiser and more cautious to initiate the original Deferasirox brand for the patients who are going to go under the oral chelating regimen and increase the daily dose more smoothly to cause patient Deferasirox through even three to four weeks for better tolerance.

show abstract

Deferasirox/deferiprone

2020

Reactions Weekly

View full text Add to dashboard Cite

<p>Successful Deferasirox Rechallenge and Treating Through Reaction in a Patient with Challenge-Proven Mild Immediate Reaction: A Case Report</p>

Cited by 6 publications

References 11 publications

Drug Repositioning by Merging Active Subnetworks Validated in Cancer and COVID-19

Drug Repositioning by Merging Active Subnetworks Validated in Cancer and COVID-19

Dermatopathological Drug Reaction in Thalassemia Major: A Case Report and a Brief Review

Deferasirox/deferiprone

Contact Info

Product

Resources

About